Clinical Trials · NCT05364944

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Name: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 1Octreotide Lanreotide

Phase: Phase 1
Recruitment status: Terminated
Sponsor: Debiopharm International SA
Enrollment: 19
Start date: May 2022
Locations: 14 sites, 8 countries
Primary endpoint: Plasma Concentration of Debio 4126 in Acromegaly and GEP-NET Participants

View Octreotide compound reference